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Antisense oligodeoxynucleotides (ODNs) appear as attract-
ive anti-hepatitis B virus (HBV) agents. We investigated in
vivo, in the duck HBV (DHBV) infection model, whether lin-
ear polyethylenimine (lPEI)-based intravenous delivery of
the natural antisense phosphodiester ODNs (O-ODNs) can
prevent their degradation and allow viral replication inhibition
in the liver. DHBV-infected Pekin ducklings were injected
with antisense O-ODNs covering the initiation codon of the
DHBV large envelope protein, either in free form (O-ODN-
AS2) or coupled to lPEI (lPEI/O-ODN-AS2). Following optim-
ization of lPEI/O-ODN complex formulation, complete O-
ODN condensation into a homogenous population of small
(20–60 nm) spherical particles was achieved. Flow cytome-
try analysis showed that lPEI-mediated transfer allowed the
intrahepatic delivery of lPEI/O-ODN-AS2 to increase three-
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Introduction
Liver is an important target for delivery of therapeutic
sequences that can knock out metabolic and viral dis-
eases-causing genes. In this regard, chronic liver infection
by hepatitis B virus (HBV) is one of the major health
problems since it leads to the development of cirrhosis
and hepatocellular carcinoma. Because actual anti-hepa-
titis B treatments such as interferon alpha and nucleoside
analogs have only partial efficacy and considerable side-
effects, there is need for the development of alternative
therapeutic strategies.1–3
In the past decade, the interest in application of anti-
sense technology to fight viral infections has been intense.
Recent studies have demonstrated antiviral effects of
antisense oligodeoxynucleotides (ODNs) for a number of
different viruses such as influenza A virus,4 herpes sim-
plex virus,5 human immunodeficiency virus,6 human
Correspondence: L Cova, INSERM U271, 151 Cours Albert Thomas, F-
69424 Lyon Cedex 03, France
Received 22 November 2000; accepted 14 March 2001
fold as compared with the O-ODN-AS2. Following 9-day
therapy the intrahepatic levels of both DHBV DNA and RNA
were significantly decreased in the lPEI/O-ODN-AS2-treated
group as compared with the O-ODN-AS2-treated, control
lPEI/O-ODN-treated, and untreated controls. In addition,
inhibition of intrahepatic viral replication by lPEI/O-ODN-AS2
was not associated with toxicity and was comparable with
that induced by the phosphorothioate S-ODN-AS2 at a five-
fold higher dose. Taken together, our results demonstrate
that phosphodiester antisense lPEI/O-ODN complexes
specifically inhibit hepadnaviral replication. Therefore we
provide here the first in vivo evidence that intravenous treat-
ment with antisense phosphodiester ODNs coupled to lPEI
can selectively block a viral disease-causing gene in the
liver. Gene Therapy (2001) 8, 874–881.
cytomegalovirus.7 For HBV, several in vitro studies have
reported efficient inhibition of viral replication and gene
expression with antisense ODNs directed against differ-
ent regions of the viral genome.8–11 The antihepadnaviral
efficacy of antisense ODNs in vivo has been investigated
in HBx gene transgenic mice,12 in woodchuck13 and duck
model.14 Offensperger et al14 showed that phosphorothio-
ate ODNs (S-ODNs) directed against the 59 region of
duck HBV (DHBV) preS/S gene (S-ODN-AS2) strongly
inhibited viral replication and gene expression in chron-
ically infected ducks. However, in all these studies,
chemically modified phosphorothiate ODNs were used
in order to confer resistance to nuclease degradation.
Their use for human therapy is hampered by high cost,
toxicity, and the potential risk that chemically modified
nucleosides will be incorporated into cellular DNA.15,16
Unmodified natural phosphodiester ODNs (O-ODNs)
would present an interesting alternative to overcome
these problems. However, they are rarely used as anti-
sense agents because of their rapid degradation by serum
and cellular nucleases.17 Among various synthetic car-
riers, linear polyethylenimine (lPEI), a polymeric DNA-
binding cation, appears of particular interest for O-ODNs
DHBV inhibition by ODN complexed to lPEI
M Robaczewska et al
875protection from degradation and for increase of their cir-
culation half-life time. The lPEI–DNA complexes enter
cells via endocytosis and the endosome buffering
capacity of lPEI prevents DNA from lysosomal degra-
dation.18 lPEI is easy to manipulate, has high stability,
low cost and flexibility with respect to size of delivered
polynucleotide.19–21 Recently, lPEI has been shown to be
an efficient vector for antisense ODN delivery into duck
hepatocytes in vitro and in vivo.22 In rodents, several in
vivo studies have investigated lPEI-mediated reporter
gene delivery for gene therapy of lung,19,20 or neurologi-
cal disorders,23 as well as antitumoral therapy.24 In all
these studies successful transgene expression was
obtained, but the therapeutic and antiviral aspects of this
approach have not yet been investigated.
In this study we have addressed the question of
whether lPEI-mediated intravenous delivery of antisense
O-ODNs could inhibit hepatitis B virus replication in the
liver. Due to the narrow host range of HBV that infects
only humans and chimpanzees, the closely related duck
hepatitis B virus (DHBV) infecting domestic Pekin ducks,
provides a very useful model for testing antihepadnaviral
strategies. We report here that intravenous injection of
ducklings with lPEI-complexed antisense phosphodiester
O-ODN-AS2, covering the initiation codon of the viral
envelope protein, leads to a significant decrease in DHBV
replication. We also demonstrate that lPEI-mediated
transfer allows significant reduction of the O-ODNs dose
required for efficient inhibition of intrahepatic viral repli-
cation. To our knowledge this is the first report demon-
strating antiviral activity of lPEI-based intravenous deliv-
ery of phosphodiester antisense ODNs in the liver.
Results
Optimization of lPEI/ODN complex formulation for
intravenous delivery
To determine the optimal conditions for intravenous
lPEI/O-ODN administration, different ratios and concen-
trations of lPEI and O-ODN in 5% sucrose were tested.
The structure and dimensions of the resulting complexes
were analyzed by transmission electron microscopy of
negatively stained complexes (data not shown). Optimal
complex formulation for intravenous injection was found
at a ratio of 6 equivalents of lPEI nitrogen per ODN phos-
phate (N/P = 6) at 0.6 mg/ml concentration, demonstrat-
ing complete ODN condensation into a homogenous
population of small spherical particles, ie with a diameter
of 20–60 nm (Figure 1). Zeta potential measurement of
the complexes revealed a strong positive surface charge
of +55 – 5 mV (n = 3).
lPEI mediates efficient delivery of phosphodiester ODNs
to the liver
To analyze the liver uptake of ODNs, lPEI/FITC-O-ODN
complexes or FITC-ODN in free form were intravenously
injected into ducklings and the hepatocyte-associated
fluorescence was analyzed by flow cytometry 24 h later.
As shown in Figure 2, the S-ODN-AS2 in free form was
efficiently delivered to the liver following injection as
assessed by high percentage (28.6%) of positive hepato-
cytes. In contrast, only weak cell-associated fluorescence
(4.7% of positive hepatocytes) was detected after injection
of O-ODN-AS2 in free form. The lPEI/O-ODN-AS2 com-
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Figure 1 Transmission electron microscopy of lPEI/O-ODN complexes.
Preparation at N/P = 6 in 5% sucrose allows formation of an homogenous
population of spherical complexes. Bar indicates 100 nm.
Figure 2 Flow cytometry analysis of hepatocytes 24 h after ODN injec-
tion. Fluorescent phosphodiester O-ODN-AS2 in lPEI-complexed or in
free form, or phosphorothioate S-ODN-AS2 were intravenously injected
into 2-week-old Pekin ducklings, as detailed in Materials and methods.
Animals were killed 24 h later and hepatocyte suspension was examined
by flow cytometry. The mean percentage of FITC-positive cells from two
animals injected with each ODN are represented. The autofluorescence of
control cells was substracted.
plexes were found in 13.9% of hepatocytes, indicating
that lPEI improves uptake of the O-ODN.
Next, confocal microscopy was used to visualize the
differences in intrahepatic distribution of S-ODN and O-
ODN. As illustrated in Figure 3, following injection of
FITC-O-ODN-AS2 in free form the staining was almost
negative (Figure 3c) and comparable to the hepatocyte
autofluorescence of uninjected duck liver (Figure 3a). By
contrast, following FITC-S-ODN-AS2 injection the
majority of liver tissue showed a homogeneously dif-
fused fluorescence (Figure 3b). Interestingly, injection of
lPEI/FITC-O-ODN-AS2 complexes led to a different pat-
tern, showing more intense staining but restricted to clus-
ters of hepatocytes (Figure 3d). This distribution pattern
was already observed 2 h after injection. Taken together,
these data demonstrate that complexation with lPEI
allows rapid and efficient delivery of O-ODN to the
liver tissue.
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Figure 3 Confocal microscopic images of liver sections 4 h after intra-
venous injection of FITC-labelled ODNs. Fluorescent staining of livers
from (a) control uninjected duck (hepatocyte autofluorescence), ducks
injected with (b) S-ODN-AS2 in free form, (c) O-ODN-AS2 in free form,
and (d) lPEI-complexed O-ODN-AS2. Original magnification · 3000.
Detection of ODNs in different organs
To assess whether other organs besides the liver retained
the circulating S-ODN-AS2 and lPEI/O-ODN-AS2 com-
plexes, sections of the kidneys, lungs and spleen were
examined by fluorescence microscopy at 4 and 24 h after
intravenous injection of FITC-ODN into ducklings. As
summarized in Table 1, S-ODN-AS2 was found in all
organs examined 24 h after injection from four out of four
injected ducks, except for lungs where three out of four
ducklings were positive, but fluorescent staining was
very weak (data not shown). The fluorescence of lPEI/O-
ODN-AS2 complexes was found in the spleen in three
out of four, and in the kidneys in two out of four animals
(Table 1), whereas the lungs remained negative in all four
injected ducklings. Interestingly, distribution of lPEI/O-
ODN-AS2 complexes in the spleen and kidney was simi-
lar to that found in the liver, ie limited to clusters of cells
(data not shown).
Impact of antisense ODN treatment on viremia
DHBV-infected ducklings have been assigned into differ-
ent treatment groups which received antisense therapy
Table 1 Detection of ODNs in different tissues
Tissue S-ODN AS2 O-ODN AS2 + lPEI
4 h 24 h 4 h 24 h
Kidney 4/4 4/4 0/4 2/4
Liver 4/4 4/4 4/4 4/4
Lung 0/4 3/4 0/4 0/4
Spleen 4/4 4/4 4/4 3/4
Ducklings were i.v. injected with 400 mg FITC-ODNs. At 4 and 24
h after injection, the distribution of ODNs over different organs was
determined by fluorescence microscopy. The results are expressed
as number of FITC-positive/number of injected ducklings.
Table 2 Therapeutic protocol
ODN administered lPEI ODN dosea No. ducks
(mg/g bw/day)
O-ODN AS2 + 1 5
O-ODN AS2 + 2 5
O-ODN AS2 + 3 3
S-ODN AS2 - 15 4
O-ODN AS2 - 3 4
O-ODN CTRL + 2 3
Untreated controls - - 4
Antisense ODN treatment of DHBV-infected ducklings was started
at day 4 after infection and followed for 9 days.
aDaily dose of administered ODNs, expressed in mg per g bw.
as summerized in Table 2. Viremia was followed daily in
the ducks from all groups. It was not possible to investi-
gate the effect of lPEI alone on viremia, since preliminary
studies showed toxicity of the polycation in the soluble
uncomplexed form (data not shown).
The follow-up of serum DHBV DNA titers in the
untreated duck group showed the typical evolution of
viremia in the DHBV-infected young ducklings, reaching
high levels at day 6–7 after infection and followed by a
decrease and fluctuation (Figure 4). Injection of a high
dose (15 mg/g bw/day) of S-ODN-AS2 significantly re-
duced viremia (P = 0.02) in treated ducklings, as meas-
ured by the decrease in the total virus release during the
treatment. Administration of O-ODN-AS2 in free form
had no effect on serum DHBV DNA compared with the
untreated controls, while a slight decrease was observed
in animals injected with unrelated lPEI/O-ODN-CTRL
complexes. The 1 mg/g bw/day dose of lPEI/O-ODN-
AS2 complexes was ineffective in inhibition of virus
release. By contrast, the treatment with 2 or 3 mg/g bw
of lPEI/O-ODN-AS2 induced dose-dependent and sig-
nificant decrease in viremia (P = 0.05 and 0.03,
respectively). We have not observed loss of weight in
lPEI/O-ODN-treated animals compared with the
untreated controls (data not shown). In addition, no
Figure 4 Effect of ODNs administration on DHBV viremia. Viral DNA
in duck serum was analyzed by dot blot hybridization during a 9-day
course of ODN antisense treatment. The level of mean DHBV DNA titers
in vge (virus genome equivalent)/ml for each group of ducks, based on
individual viremia titers, is represented. Arrow indicates the beginning
of treatment.
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Figure 5 Analysis of serum lactic acid levels at day 5 of ODN treatment
of ducklings. Bars represent the mean of lactic acid concentration in
mmol/l of serum for each duck group, based on individual titers. Standard
deviations are indicated.
increase in the lactic acid levels was detected in the sera
of lPEI/O-ODN-AS2-treated duck group as compared
with the S-ODN-AS2-treated and untreated controls
(Figure 5). Moreover, the histological analysis of the auto-
psy liver samples revealed that DHBV infection induced
only mild hepatitis characterized by portal infiltration
that was similar for lPEI/O-ODN-treated and untreated
ducks (data not shown). Taken together, these data
suggest absence of toxicity following lPEI complex
treatment.
lPEI-delivered O-ODN-AS2 decrease intrahepatic DHBV
replication
To evaluate the effect of antisense ODNs on viral repli-
cation, intrahepatic DHBV DNA and RNA levels were
analyzed at the end of the treatment. Southern blot analy-
sis of viral DNA showed that treatment with either unre-
lated lPEI/O-ODN-CTRL complexes (Figure 6a) or O-
ODN-AS2 in free form (not shown) had no effect on
intrahepatic DHBV DNA, whose level was comparable
Figure 6 Analysis of intrahepatic viral replication at the end of antisense
ODNs treatment. (a) Southern blot of total liver DNA (5 mg/lane). The
positions of relaxed circular (RC), linear (L), and single-stranded (SS)
viral DNAs are indicated, as are the therapeutic protocols. (b) Total RNA
analysed by Northern blot (3 mg of RNA/lane). Arrows show positions
of the pregenomic RNA (3.2 kb) and RNAs (2.4 and 2.1 kb) encoding the
large and small DHBV envelope proteins, respectively. Control for equal
RNA loading was established by quantification of 28S RNA (data not
shown).
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with that of untreated controls. As illustrated in Figure
6a, the treatment with a high dose (15 mg/g bw/day) of
S-ODN-AS2 in free form decreased viral DNA synthesis
as compared with the controls. No inhibition of
intrahepatic viral DNA was observed in animals treated
with 1 mg/g bw/day of lPEI/O-ODN-AS2 complexes
(data not shown). By contrast, administration of 2 or 3
mg/g bw/day of lPEI/O-ODN-AS2 complexes led to a
decrease, in a dose-dependent manner of DHBV DNA
replicative forms (Figure 6a). In all treated animals, the
viral covalently closed circular DNA (cccDNA) was still
detected at the end of treatment (data not shown).
Northern blot analysis revealed that lPEI-/O-ODN-
CTRL complexes (Figure 6b) and O-ODN-AS2 in free
form (not shown) had no inhibitory effect on intrahepatic
viral RNA levels. Following treatment with S-ODN-AS2
(Figure 6b) all forms of intrahepatic viral RNA were
decreased. The pregenomic RNA (3.2 kb), that is the tem-
plate of DHBV replication, was decreased to the same
extent as the 2.4 and 2.1 kb RNAs encoding the large and
small envelope proteins, respectively. Similarly, the treat-
ment with lPEI/O-ODN-AS2 complexes resulted in a
marked decrease in all viral RNAs, which was observed
for 2 or 3 mg/g bw/day doses (Figure 6b).
Taken together, these results indicate that both the
appropriate sequence of O-ODN and its complexation
with lPEI were required to obtain the inhibition of
intrahepatic DHBV replication. The densitometric analy-
sis of Southern and Northern blots (Figure 7a and b)
revealed that the decrease in DHBV DNA and RNA
obtained with 2 or 3 mg of lPEI/O-ODN-AS2 complexes
was significant as compared with untreated controls (P =
0.02 and 0.03, respectively). Interestingly, the decrease in
viral DNA and RNA induced by lPEI/O-ODN-AS2 com-
plexes at 3 mg dose was comparable with the decrease
observed for S-ODN-AS2 in free form at a five-fold
higher dose (Figure 7a and b).
Effect of antisense treatment on DHBV gene expression
Finally, we investigated whether reduction of DHBV
RNA levels was associated with the decrease in viral
envelope and capsid expression in the liver. Although
both the 15 mg/g bw S-ODN-AS2 in free form and 3 mg/g
bw lPEI/O-ODN-AS2 complexes inhibited DHBV RNA
to the same extent, immunoblotting analysis revealed
that the decrease in 32 kDa DHBV core and 36 kDa
DHBV preS/S envelope protein expression were more
pronounced in S-ODN-AS2-treated than in lPEI/O-ODN-
AS2 complexes-treated animals (P = 0.02 and 0.07,
respectively), as compared with untreated (Figure 8a and
b), O-ODN-AS2 and lPEI/O-ODN-CTRL-treated controls
(data not shown). Densitometric analysis of the immuno-
blotting forms showed that in animals treated with S-
ODN-AS2 the DHBV core protein expression was
inhibited to a larger extent than the DHBV envelope
protein (Figure 8c).
Discussion
In the present study, we report that intravenously admin-
istrated natural phosphodiester antisense ODNs, when
complexed to lPEI, can specifically inhibit hepadnaviral
replication in vivo. To study the antiviral potential of anti-
sense lPEI/O-ODN-AS2 complexes, we have used the
DHBV-infected Pekin duck, which is a reference model
DHBV inhibition by ODN complexed to lPEI
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Figure 7 Densitometric analysis of intrahepatic DHBV DNA and RNA
levels at the end of treatment. Relative band intensity of all DHBV DNA
replicative forms (a) from Southern blot (Figure 6a) and RNA forms (b)
from Northern blot (Figure 6b) were quantified by densitometry. The bars
represent the mean relative band intensity for each group of treated ducks.
Standard deviations are indicated. *P , 0.05 was considered as significant
compared with untreated controls.
validated by us and others for screening of anti-HBV
approaches.25–28 Offensperger et al14 have previously
reported in this model that antisense phosphorothioate
S-ODN-AS2 covering the initiation codon of the DHBV
envelope protein can efficiently inhibit DHBV replication.
Since S-ODN are expensive and potentially toxic, we
have tested whether the natural O-ODN-AS2 of the same
sequence coupled to an efficient carrier could represent
an alternative antiviral strategy. We have chosen lPEI
because it is a particularly efficient polycationic vector
with endosome buffering capacity that provides protec-
tion of complexed DNA from lysosomal degradation.18
Following intravenous injection of FITC-O-ODN-AS2 in
free form into ducklings, only weak hepatocyte-associa-
ted fluorescence was detected by flow cytometry, in
agreement with their known rapid degradation by nucle-
ases. Although the lPEI-mediated transport of O-ODNs
was not liver-targeted, we observed a three-fold increase
in their liver delivery following complex formation with
Figure 8 Effect of antisense ODNs on DHBV protein expression in duck
livers at the end of treatment. Liver proteins from untreated, S-ODN-
AS2-treated and lPEI/O-ODN-AS2-treated ducks were revealed in immu-
noblotting assay with: (a) polyclonal anti-DHBV preS protein rabbit
serum; arrows indicate the 36 kDa DHBV preS/S envelope protein and
its 28 kDa cleavage product; (b) polyclonal anti-DHBV core protein rabbit
serum; the position of the 32 kDa major DHBV core protein is indicated
by arrow. (c) Densitometric analysis of immunoblottings presented above.
The mean relative band intensity and standard deviations are shown. *P
, 0.05 was considered as significant compared with untreated controls.
lPEI. The small size (20–60 nm) of lPEI/O-ODNs com-
plexes prepared in our study may have contributed to
their filtration by liver sinusoids and successful delivery
to hepatocytes. However, taking into account the strong
positive surface charge of these complexes, we cannot
exclude that after intravenous injection they interact with
plasma proteins forming larger aggregates, a part of
which could still be capable of passing through the liver
sinusoids. After leaving the circulation the aggregated
complexes may transfect several neighboring cells and
this could explain the presence of the intensively stained
lPEI/FITC-O-ODN clusters seen by confocal microscopy
in the liver. A similar pattern of clusters of O-ODN-
associated fluorescence was observed in the spleen and
kidneys, but not in the lungs.
The main objective of this study was to investigate
whether intravenous injection of low doses of unmodi-
fied antisense O-ODN-AS2 coupled to lPEI was able to
inhibit hepadnaviral replication in vivo. The target region
of ODN-AS2 is present on both the pregenomic (3.2 kb)
and the subgenomic preS/S (2.4 kb) DHBV RNA. Since
the pregenomic RNA is the template for reverse tran-
scription, it is not surprising that all forms of viral RNA
have been decreased following treatment with lPEI/O-
ODN-AS2. In addition, a dose-dependent and significant
decrease in intrahepatic DHBV DNA was observed in
lPEI/O-ODN-AS2 complex-treated ducklings. We have
DHBV inhibition by ODN complexed to lPEI
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O-ODN-AS2 in free form or the unrelated lPEI/O-ODN-
CTRL complexes of the same size and linkage failed to
have any effect on viral replication in the liver. The
decrease in viremia in lPEI/O-ODN-AS2-treated animals
was also dose-dependent and reflects the decrease in
intrahepatic DHBV RNA and DNA. However, we cannot
exclude that part of this decrease in circulating viral par-
ticles is due to their interaction with positively charged
lPEI/O-ODN complexes or some free lPEI probably
present in blood. The aggregates between lPEI, virions
and serum proteins could have been depleted during the
centrifugation step of serum samples preparation.
Whether this contributed to the slight decrease in viremia
observed in the control lPEI/O-ODN-CTRL-treated ani-
mals in the absence of a corresponding decrease in
intrahepatic viral DNAs, RNAs and proteins, is unknown
and would require further investigation.
We have observed a toxicity of lPEI in free form when
intravenously injected into ducklings. lPEI is a positively
charged macromolecule designed to interact electro-
statically with the phosphates on DNA to form compact
particles. In the absence of DNA this free macromolecule
may interact with every negatively charged component
such as cells and serum proteins, leading to toxicity. In
addition, the ‘naked’ polycations were shown to be
strong complement activators, but following complex for-
mation with DNA the complement activation was sig-
nificantly reduced.29 We cannot exclude that after com-
plex formation between lPEI and ODN there is still some
free lPEI left. However, we have observed no toxicity in
lPEI/O-ODN-treated animals as reflected by the absence
of variations in duck weight, serum lactic acid levels and
liver pathology as compared with the untreated controls.
Interestingly, the intrahepatic DHBV DNA and RNA
levels were inhibited to comparable levels when duck-
lings were treated with 15 mg/g bw/day dose of S-ODN-
AS2 in free form or a five-fold lower dose (3 mg/g
bw/day) of lPEI/O-ODN-AS2 complexes. It may be
possible that complexation with lPEI favors O-ODN-AS2
delivery to the hepatocyte nuclei, where the key steps of
DHBV replication take place. This would be in agreement
with the fact that PEI can promote transgene delivery to
the nucleus of mammalian cells.30 The comparison of
intrahepatic DHBV proteins expression showed that S-
ODN-AS2 induced a more marked decrease in viral core
and preS/S proteins than the lPEI/O-ODN-AS2. This
suggests that the intranuclear viral replication was
inhibited in a comparable manner by both S-ODN-AS2
and lPEI/O-ODN-AS2 complexes, although a five-fold
excess of S-ODN-AS2 more efficiently blocked the protein
translation step within hepatocyte cytoplasm. The
reduced intrahepatic production of DHBV core and
DHBV preS/S proteins in the S-ODN-AS2-treated ducks
may explain the more important decrease in their viremia
as compared with the lPEI/O-ODN-AS2 complex-treated
group. Whether the differences in the intrahepatic DHBV
nucleic acids and proteins inhibition following treatment
by lPEI/O-ODN and S-ODN are related to the mech-
anisms of their cellular uptake or intracellular distri-
bution is actually not known and requires further investi-
gation. Although the therapy with lPEI/O-ODN-AS2 at
2 and 3 mg/g bw/day led to a significant decrease in
intrahepatic viral replication, we have not achieved com-
plete viral elimination. To improve the efficacy of
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lPEI/O-ODN treatment one experimental approach
would consist of using combination of antisense O-ODN
directed to different parts of the viral genome. In
addition, in this study the delivery of lPEI/O-ODN com-
plexes was performed by the intravenous route and was
not liver specific. The liver targeted delivery of lPEI/O-
ODN via specific hepatocyte receptors may increase the
efficiency of its transfer into cells and warrants further
studies.
Taken together, we provide first experimental evidence
that intravenous treatment with phosphodiester anti-
sense ODN coupled to lPEI results in a specific and sig-
nificant inhibition of hepadnaviral replication, suggesting
its usefulness for therapy of hepatitis B. In addition, we
demonstrate that the lPEI-mediated transfer allows the
reduction of the amount of antisense O-ODNs required
for efficient inhibition of hepadnaviral replication. The
simple and inexpensive approach presented here can be
of particular interest for different studies aiming to use
the intravenous delivery of antisense O-ODN to block
other viral or cellular disease-causing genes in the liver.
Materials and methods
Virus
A pool of viremic sera from ducklings infected with the
DHBV strain sequenced by Mandart et al31 was used as
inoculum. This inoculum was quantified into virus gen-
ome equivalents (vge) by quantitative dot blot hybridiz-
ation as previously described.32
Animals
Three-day-old Pekin ducklings (Anas domesticus) were
intravenously inoculated with a DHBV-positive serum (5
· 107 vge per duck), as previously described.24 Ducklings
were maintained in accordance with the guidelines for
animal care at the facilities of the Ecole Nationale
Ve´te´rinaire de Lyon, France.
Oligodeoxynucleotides
Unlabelled or 59-fluorescein-labelled (FITC) phosphodies-
ter (O-ODN) and phosphorothioate (S-ODN) 18-mers
were synthesized by Birsner and Grob GmbH,
Denzlingen, Germany. The antisense ODN-AS214
directed against the start of the DHBV preS region (nt
795–812: 59-ATGTTGCCCCATCATAAA-39) was used in
S-ODN or O-ODN form. In addition, an unrelated O-
ODN (O-ODN-CTRL) of the same size (59-
TGTTGTTGCCCATTATGT-39) was used as a control for
possible non-specific effects.
lPEI/O-ODN complex formation and zeta potential
measurements
Linear lPEI (mean MW 22 kDa) was produced as pre-
viously described.18 For intravenous delivery, complexes
were prepared at a 6:1 lPEI nitrogen/ODN phosphate
ratio (N/P = 6). Typically, 500 mg of O-ODN and the cor-
responding amount of a 1 m lPEI solution were each
diluted into 400 ml of 5% sucrose and incubated for 10
min at room temperature (RT). Subsequently, the lPEI
solution was added to the O-ODN solution, vortexed and
incubated for 10 min at RT to allow complex formation.
Immediately after incubation, the lPEI/O-ODN com-
plexes were rapidly intravenously injected to ducklings
avoiding their mixing with blood flow.
DHBV inhibition by ODN complexed to lPEI
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The zeta potential of the lPEI/O-ODN complexes was
determined using a Zetamaster 3000 (Malvern Instru-
ments, Orsay, France), as previously described.33
Electron microscopy of lPEI/O-ODN complexes
Carbon films were prepared by sublimation of freshly
cleaved mica, recovered by flotation on Cu/Rh grids (300
mesh; Touzard and Matignon, Courtaboeuf, France), and
dried overnight. Immediately before sample addition,
grids were glow-discharged (110 mV, 25 s). A drop (5 ml)
of sample solution was left on the grid for 1 min. Com-
plexes were negatively stained with 30 ml of aqueous ura-
nylacetate (1% wt/wt) for 20 s. Observations were perfor-
med at 80 kV with a Philips EM 410 transmission
electron microscope.30,33
Therapeutic protocol
A total of 28 Pekin ducklings experimentally infected
with DHBV as described above, was used in this study.
Ducklings were randomly assigned into seven groups
which were treated either with lPEI/O-ODN-AS2 com-
plexes (1 to 3 mg/g bw/day), or with free S-ODN-AS2 (15
mg/g bw/day) as summarized in Table 2. Control groups
included animals injected either with free O-ODN-AS2,
or with unrelated lPEI/O-ODN-CTRL complexes, or
untreated (Table 2). Ducklings received daily intravenous
injection of ODN into the foot vein and in the retrooccipi-
tal sinus starting on day 4 after infection and over 9 days.
Blood samples were collected daily for viremia follow-
up. Cellular toxicity was evaluated by analyzing the
serum lactic acid level 5 days after the beginning of treat-
ment (Lactate PAP; BioMe´rieux, Marcy l’Etoile, France).
In addition, animal weight was taken every day. All ani-
mals were killed 24 h after the end of therapy and speci-
mens of liver tissue were frozen at - 80° C for molecular
analysis, and fixed for histological analysis.
Biodistribution of ODNs
To assess the organ distribution of antisense ODN, about
1 mg/g bw (400 mg per duckling weighing 350–400 g)
of flurescein-labeled FITC-S-ODN-AS2 or FITC-O-ODN-
AS2 (complexed to lPEI or in free form) was injected into
the foot vein of 2-week-old DHBV-infected ducklings.
Four groups of four animals were killed 4 or 24 h after
ODN injection, and frozen liver, spleen, lungs and kid-
neys sections were examined by fluorescence microscopy
(Leica, France; DMLB100). Intrahepatic localization of
ODN was additionally analyzed by confocal microscopy
(Zeiss, Germany; LSM). Excitation of green fluorescence
of FITC-ODN at 488 nm was achieved with argon laser,
with the resulting fluorescence wavelengths observed at
515–545 nm.
In adition, to quantify by flow cytometry the ODN
delivery to the liver during the antisense therapy, the last
treatment injection of ODN consisted of a mixture of
unlabeled and 400 mg FITC-labeled ODN. Single-cell sus-
pensions of liver cells were prepared by collagenase
digestion of 0.5 g fresh liver tissue 24 h after ODN injec-
tion. The percentage of FITC-positive hepatocytes was
assessed by flow cytometry (FACScan, Lysys II Software,
Becton Dickinson) by analyzing fluorescence from 10000
individual hepatocytes.
Detection of viral replication
DHBV DNA was detected in 50 ml of duck serum by dot
blot hybridization by using a full-length 32P-labelled
DHBV probe as described previously.34 Total liver DNA
was obtained from 0.2 g of frozen tissue homogenized
in liquid nitrogen as described.35 For intrahepatic DHBV
DNA detection, 5 mg of the total DNA was subjected to
electrophoresis on 1% agarose gel, followed by Southern
blot analysis.35
Total RNA was isolated from frozen liver by liquid
nitrogen homogenization and incubation in TRIZOL
Reagent (Life Technologies). Three mg of purified RNA
were glyoxalated, separated on 1% agarose gel and
analyzed by Northern blot.36
Immunoblotting
Proteins were extracted from duck livers as previously
described.36 Immunoblotting of DHBV envelope and core
proteins was performed on 200 mg of total proteins, using
polyclonal rabbit antiserum directed against the DHBV
preS region34 or against DHBV core protein, anti-rabbit
peroxidase conjugate (DAKO A/S, diluted 1:2000), and
ECL chemiluminescence detection kit (Amersham), as
previously described.32
Histopathology
Sections of fixed liver tissue were examined under code.
For each sample, portal inflammation, ductular prolifer-
ation, lobular necrosis, and hepatocyte degeneration were
semi-quantitatively scored according to their degree, as
previously described.36
Quantification of viral markers and statistical analysis
The mean area under the curves of viremia, which
reflects total virus production, was compared between
duck groups. Comparative densitometry of autoradio-
graphs were performed by densitometric analysis using
a scanner apparatus (Canon, France; CLC 10). The com-
parison between antisense ODN-treated and untreated
groups for all viral replication and gene expression mark-
ers was performed by the nonparametric Mann–Whitney
test. Statistical significance was taken as P , 0.05.
Acknowledgements
We thank Darius Moradpour for stimulating discussion,
advice and critcal review of the manuscript. The excellent
assistance of C Jamard with animals is gratefully
acknowledged. MR was the recipient of fellowships from
Re´gion Rhoˆne-Alpes (TEMPRA), French Ministe`re des
Affaires Etrange`res and Association pour la Recherche
sur le Cancer (ARC). WBO and HEB acknowledge sup-
port by the Zentrum fu¨r Klinische Forschung I, Univer-
sity of Freiburg, Germany, and by grant Of 14/4–2 from
the Deutsche Forschungsgemeinschaft. This work was
supported in part by a grant from TEMPRA and from
ARC.
References
1 Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral
hepatitis. New Engl J Med 1997; 336: 347–356.
2 Zoulim F. Therapy of chronic hepatitis B virus infection: inhi-
bition of the viral polymerase and other antiviral strategies.
Antiviral Res 1999; 44: 1–30.
3 Farrell GC. Clinical potential of emerging new agents in hepa-
titis B. Drugs 2000; 60: 701–10.
4 Mizuta T et al. Antisense oligonucleotides directed against the
viral RNA polymerase gene enhance survival of mice infected
with influenza A. Nat Biotechnol 1999; 17: 583–587.
DHBV inhibition by ODN complexed to lPEI
M Robaczewska et al
8815 Kulka M et al. Antiviral effect of oligo(nucleoside methyl-
phosphonates) complementary to the herpes simplex virus type
1 immediate early mRNAs 4 and 5. Antiviral Res 1993; 20:
115–130.
6 Lisziewicz J et al. Long-term treatment of human immunodefi-
ciency virus-infected cells with antisense oligonucleotide phos-
phorothioates. Proc Natl Acad Sci USA 1993; 90: 3860–3864.
7 Perry CM, Balfour JA. Fomivirsen. Drugs 1999; 57: 375–380.
8 Goodarzi G, Gross SC, Tewari A, Watabe K. Antisense oligo-
deoxyribonucleotides inhibit the expression of the gene for
hepatitis B virus surface antigen. J Gen Virol 1990; 71: 3021–3025.
9 Blum HE, Galun E, Weizsacker F, Wands JR. Inhibition of hepa-
titis B virus by antisense oligodeoxynucleotides (letter). Lancet
1991; 337: 1230.
10 Korba BE, Gerin JL. Antisense oligonucleotides are effective
inhibitors of hepatitis B virus replication in vitro. Antiviral Res
1995; 28: 225–242.
11 Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B
virus replication by targeted pretreatment of complexed anti-
sense DNA in vitro. Hepatology 1996; 23: 1297–1303.
12 Moriya K, Matsukura M, Kurokawa K, Koike K. In vivo inhi-
bition of hepatitis B virus gene expression by antisense phos-
phorothioate oligonucleotides. Biochem Biophys Res Commun
1996; 218: 217–223.
13 Bartholomew RM et al. Targeted delivery of antisense DNA in
woodchuck hepatitis virus-infected woodchucks. J Viral Hepat
1995; 2: 273–278.
14 Offensperger WB et al. In vivo inhibition of duck hepatitis B virus
replication and gene expression by phosphorothioate modified
antisense oligodeoxynucleotides. EMBO J 1993; 12: 1257–1262.
15 Plenat F. Animal models of antisense oligonucleotides: lessons
for use in humans. Mol Med Today 1996; 2: 250–257.
16 Agrawal S, Zhao Q. Antisense therapeutics. Curr Opin Chem Biol
1998; 2: 519–528.
17 Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics
of antisense oligonucleotides. Clin Pharmacokinet 1995; 28: 7–16.
18 Boussif O et al. A versatile vector for gene and oligonucleotide
transfer into cells in culture and in vivo: polyethylenimine. Proc
Natl Acad Sci USA 1995; 92: 7297–7301.
19 Ferrari S et al. ExGen 500 is an efficient vector for gene delivery
to lung epithelial cells in vitro and in vivo. Gene Therapy 1997; 4:
1100–1106.
20 Goula D et al. Polyethylenimine-based intravenous delivery of
transgenes to mouse lung. Gene Therapy 1998; 5: 1291–1295.
21 Zou S, Erbacher P, Remy JS, Behr JS. Systemic linear polyethy-
lenimine (L-PEI)-mediated gene delivery in the mouse. J Gene
Med 2000; 2: 128–134.
Gene Therapy
22 Chemin I et al. Liver-directed gene transfer: a linear polyethleni-
mine derivative mediates highly efficient DNA delivery to pri-
mary hepatocytes in vitro and in vivo. J Viral Hepat 1998; 5:
369–375.
23 Goula D et al. Size, diffusibility and transfection performance of
linear PEI/DNA complexes in the mouse central nervous sys-
tem. Gene Therapy 1998; 5: 712–717.
24 Coll JL et al. In vivo delivery to tumors of DNA complexed with
linear polyethylenimine. Hum Gene Ther 1999; 10: 1659–1666.
25 Lin E et al. The guanine nucleoside analog penciclovir is active
against chronic duck hepatitis B virus infection in vivo. Anti-
microb Agents Chemother 1996; 40: 413–418.
26 Zoulim F, Trepo C. New antiviral agents for the therapy of
chronic hepatitis B virus infection. Intervirology 1999; 42: 125–
144.
27 Rollier C et al. Protective and therapeutic effect of DNA-based
immunization against hepadnavirus large envelope protein.
Gastroenterology 1999; 116: 658–665.
28 Le Guerhier F et al. Characterization of the antiviral effect of
29,39-dideoxy-29, 39-didehydro-beta-L-5-fluorocytidine in the
duck hepatitis B virus infection model. Antimicrob Agents Chem-
other 2000; 44: 111–122.
29 Plank C, Mechtler K, Szoka FC, Wagner E. Activation of the
complement system by synthetic DNA complexes: a potential
barrier for intravenous gene delivery. Hum Gene Ther 1996; 7:
1437–1446.
30 Pollard H et al. Polyethylenimine but not cationic lipids pro-
motes transgene delivery to the nucleus in mammalian cells. J
Biol Chem 1998; 273: 7507–7511.
31 Mandart E, Kay A, Galibert F. Nucleotide sequence of a cloned
duck hepatitis B virus genome: comparison with woodchuck
and human hepatitis B virus sequences. J Virol 1984; 49: 782–792.
32 Borel C et al. Phosphorylation of DHBV pre-S: identification of
the major site of phosphorylation and effects of mutations on
the virus life cycle. Virology 1998; 242: 90–98.
33 Erbacher P et al. Transfection and physical properties of various
saccharide, poly(ethylene glycol), and antibody-derivatized
polyethylenimines (PEI). J Gene Med 1999; 1: 210–222.
34 Lambert V et al. Virus-neutralizing monoclonal antibody to a
conserved epitope on the duck hepatitis B virus pre-S protein.
J Virol 1990; 64: 1290–1297.
35 Cova L et al. Duck hepatitis B virus infection, aflatoxin B1 and
liver cancer in domestic Chinese ducks. Br J Cancer 1994; 69:
104–109.
36 Barraud L et al. Enhanced duck hepatitis B virus gene expression
following aflatoxin B1 exposure. Hepatology 1999; 29: 1317–1323.
